lifestyle.pspl.com

Author: ELI LILLY AND COMPANY

Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)

February 19, 2026
Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

February 18, 2026
Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

February 16, 2026
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company

February 16, 2026
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

February 16, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies

February 12, 2026
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

February 11, 2026
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

February 10, 2026
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

January 24, 2026
Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

January 22, 2026